AcelRx Story

Our current take on AcelRx (NASDAQ:ACRX) analyst consensus
What is the right price you would pay to acquire a share of AcelRx Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with AcelRx Pharmaceuticals this year

Annual and quarterly reports issued by AcelRx Pharmaceuticals are formal financial statements that are published yearly and quarterly and sent to AcelRx stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as AcelRx Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How AcelRx utilizes its cash?

To perform a cash flow analysis of AcelRx Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash AcelRx Pharmaceuticals is receiving and how much cash it distributes out in a given period. The AcelRx Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. AcelRx Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. AcelRx Pharmaceuticals reported Net Cash Flow from Operations of (46.06 Million) in 2020

Acquisition by Richard Afable of 15000 shares of AcelRx Pharmaceuticals subject to Rule 16b-3

Legal trades by AcelRx Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

AcelRx insider trading alert for grant of stock option (right to buy) by Richard Afable, the corporate stakeholder, on 16th of June 2020. This event was filed by Acelrx Pharmaceuticals In with SEC on 2020-06-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

About Contributor